Previous 10 | Next 10 |
WILMINGTON, Del., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Prelude Therapeutics Inc. (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that Kris Vaddi, PhD, Chief Executive Officer, will participate in a fireside chat at the 4 th Annual Evercore ISI HealthCONx Confer...
Prelude Therapeutics (NASDAQ:PRLD): Q3 GAAP EPS of -$0.66 misses by $0.02. Cash, cash equivalents, and marketable securities of $320.9M. Press Release For further details see: Prelude Therapeutics EPS misses by $0.02
PRT543 and PRT811 Demonstrate Favorable Safety Profile, Tolerability and Evidence of Preliminary Clinical Activity in Phase 1 Dose Escalation in Unselected Patients Phase 1 Dose Expansion Ongoing in Biomarker-Selected Solid Tumor and Hematologic Malignancy Expansion Cohorts for ...
Prelude Therapeutics (NASDAQ:PRLD) announces that the U.S. FDA has accepted the Investigational New Drug (IND) application for its precision oncology candidate, PRT2527, which is designed to be a potent and selective CDK9 inhibitor. In preclinical studies, PRT2527 was shown to reduce MCL1 and...
WILMINGTON, Del., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Prelude Therapeutics Inc. (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that the United States Food and Drug Administration (FDA) has accepted the Investigational New Drug (IND) application for its precision ...
Gainers: AlloVir (NASDAQ:ALVR) +14%, InflaRx (NASDAQ:IFRX) +14%, Harmony Biosciences (NASDAQ:HRMY) +13%, Omeros (NASDAQ:OMER) +11%, Prelude Therapeutics (NASDAQ:PRLD) +11%. Losers: Galera Therapeutics (NASDAQ:GRTX) -68%, Atea Pharmaceutic...
Listen on the go! A daily podcast of Wall Street Breakfast's Alpha Talks will be available this morning on Seeking Alpha, iTunes, Stitcher and Spotify. Stocks and U.S. Treasurys fell Friday after a weak jobs report added to speculation about the Federal Reserve's plan to taper its bond-buying...
While the S&P 500 index eked out a ~0.8% gain over the week, its healthcare constituents slipped ~0.3% to record the fifth consecutive weekly loss. Dragged down by biotech stocks, the sector became the second-worst performer in the index. Among healthcare stocks with more than $...
Gainers: Camber Energy (NYSE:CEI) +97%. Merus (NASDAQ:MRUS) +32%. New Fortress Energy (NASDAQ:NFE) +25%. Paltalk (NASDAQ:PALT) +25%. Grom Social Enterprises (NASDAQ:GROM) +20%. DatChat (NASDAQ:DATS) +20%. Jupiter Wellness (NASDAQ:JUPW) +18%. NextPlay Technologies (NASDAQ:NXTP) +19%. Independe...
Gainers: Merus (NASDAQ:MRUS) +36%, Nutriband (OTCQB:NTRB) +16%, Skylight Health (NASDAQ:SLHG) +16%, Rani Therapeutics (NASDAQ:RANI) +12%, Jupiter Wellness (NASDAQ:JUPW) +12%. Losers: Osmotica Pharmaceuticals (NASDAQ:OSMT) -38%, Prelude Therapeutics (NAS...
News, Short Squeeze, Breakout and More Instantly...
Prelude Therapeutics Incorporated Company Name:
PRLD Stock Symbol:
NASDAQ Market:
Prelude Therapeutics Incorporated Website:
2024-07-27 22:24:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-20 07:00:07 ET Peter Lawson from Barclays issued a price target of $3.00 for PRLD on 2024-06-20 05:33:00. The adjusted price target was set to $3.00. At the time of the announcement, PRLD was trading at $3.87. The overall price target consensus is at $10.67 with ...
WILMINGTON, Del., June 03, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the Company will participate in two upcoming healthcare conferences in June. Jefferies Global Healthcare Conference 2...